Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZL-1310 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Exploration (Part 1) | EXPERIMENTAL | Multiple dose levels of ZL-1310 will be explored in combination with tarlatamab administered intravenously (IV). |
| Dose Expansion (Part 2) | EXPERIMENTAL | ZL-1310 will be administered IV at the selected maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) in combination with tarlatamab administered IV. |
| Triplet Combination (Part 3) | EXPERIMENTAL | ZL-1310 will be administered at MTCD or RP2D in combination with tarlatamab and an anti-PD-L1 (durvalumab) each administered IV. |
| Name | Type | Description |
|---|---|---|
| ZL-1310 | DRUG | ZL-1310 will be administered as an IV infusion. |
| Tarlatamab | DRUG | Tarlatamab will be administered as an IV infusion. |
| Durvalumab | DRUG | Durvalumab will be administered as an IV infusion. |
Inclusion Criteria: * Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent. * Participants with Histologically or cytologically confirmed SCLC: * For Part 1, participants must have SCLC that has progressed or recurred following ...
Top 20 of 84 competitors
ZL-1310 is an investigational small molecule being studied for the treatment of Small Cell Lung Cancer (SCLC). It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being evaluated in combination with other therapies to assess its safety and efficacy in patients with this disease.
ZL-1310 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. Amgen is conducting a Phase 1 clinical trial to evaluate the drug in patients with Small Cell Lung Cancer.
ZL-1310 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is recruiting participants to study the drug's safety, tolerability, and preliminary efficacy in Small Cell Lung Cancer.
ZL-1310 is being studied in a Phase 1 clinical trial with the identifier NCT07531095. This trial is titled 'Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)' and is currently recruiting participants. The trial is enrolling approximately 160 patients across multiple countries, including the United States, Australia, and several European nations.
No, ZL-1310 is not the same as tarlatamab. ZL-1310 is a separate investigational small molecule being developed by Amgen. In the ongoing Phase 1 clinical trial, ZL-1310 is being studied in combination with tarlatamab, with or without an anti-PD-L1 agent, for the treatment of Small Cell Lung Cancer.